Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
Pharmabiz6d
Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta
Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...
Managed Healthcare Executive9d
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH
Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...
Healio11d
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
pulmonologyadvisor3d
Sotatercept Trial Ends Due to Positive Clinical Program Efficacy Data
The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.
thecardiologyadvisor.com7d
Treprostinil for PAH Benefits Patients Who Have Cardiovascular Comorbidities
Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.
Science Daily7d
Hypertension News
Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...